Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.
Also called NCT04419467
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 114 participants
- Sponsor
- Registry
-
NCT04419467
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Israel, New Zealand, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT04419467. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-14 (actual); primary completion 2022-10-24 (actual). Results posted on 2023-12-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
- Condition
- Diabetic Kidney Disease (DKD)
- Intervention (Biological)
- CSL346
- Intervention (Drug)
- Placebo
- Lead sponsor
- CSL Behring
Record details
- Record id
cardio:ct-nct04419467- Content hash
e000ed3e0ffb5bfee98867b22c6082ba811f8ab635a671f8c33df10137cc12f7